Early-Stage Device Firms Challenge CV Big Five With Alternatives, Adjuncts
This article was originally published in The Gray Sheet
Small companies at the research stage are asking investors to support cardiovascular technology projects that would fill treatment gaps left open by surgical interventions and large firms' stent technologies
You may also be interested in...
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says
Acorn Cardiovascular's Category A "experimental" device designation for its CorCap cardiac support device represents a competitive barrier particularly problematic for smaller companies, according to VP-Corporate Assurance Steve Anderson
Acorn Cardiovascular expects to complete enrollment for a 300-patient, randomized trial of its CorCap cardiac support device for heart failure by July